Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab/relatlimab - Bristol-Myers Squibb

Next Previous
Drug Profile

Nivolumab/relatlimab - Bristol-Myers Squibb

Alternative Names: BMS-936558/BMS-986016; BMS-986213; Nivolumab and relatlimab-rmbw - Bristol-Myers Squibb; Nivolumab/relatlimab-rmbw - Bristol Myers Squibb; Opdualag; Relatlimab-rmbw/nivolumab - Bristol Myers Squibb; Relatlimab/nivolumab - Bristol Myers Squibb

Latest Information Update: 22 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer; Gastric cancer; Solid tumours
  • Phase II Squamous cell cancer
  • Phase I Haematological malignancies

Most Recent Events

  • 18 Jan 2024 Bristol-Myers Squibb completes a phase-II clinical trials in Gastric cancer (Adjunctive treatment, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Argentina, Belgium, Canada, Chile, France, Germany, Italy, Norway, Puerto Rico, Singapore, Spain, United Kingdom, Australia, Austria, Czhezia, Poland(IV) (NCT03662659)
  • 08 Nov 2023 Bristol-Myers Squibb initiates enrolment in the phase II trial for Malignant melanoma (First-line therapy, Late-stage disease, Metastatic disease) in USA (IV)
  • 26 Oct 2023 Bristol-Myers Squibb plans a phase II trial for Malignant melanoma (Metastatic disease, First-line therapy) in USA, Argentina, Chile, Greece, Italy, and Spain (IV, SC) in December 2023 (NCT06101134)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top